Get Your Complimentary e-Pass to the Cell & Gene Therapy Bioprocessing & Commercialization Digital Week!

Join us for the four days of learning at the Cell & Gene Therapy Bioprocessing & Commercialization Digital Week, a complimentary webinar series focused on the innovative science and technologies needed to overcome bottlenecks and pain points in the manufacture and commercialization of cell, gene and immunotherapies.

RSVP Your Complimentary Pass: https://goo.gl/QFKkbE

What’s on the agenda?

Continue reading “Get Your Complimentary e-Pass to the Cell & Gene Therapy Bioprocessing & Commercialization Digital Week!”

Single-use technology: The future of the bioprocessing industry?

Single-use technologies was one of the key topics at this year’s BioProcess International European Summit with a number of leading industry figures putting it in the spotlight.

“From hypothesis to market it takes an average of 10 years & $2.7 billion per drug, which puts a lot of pressure on bioprocessing.”

In a single sentence Wolfgang Kuhne, Vice President Technical Development Bioprocessing and Clinical Supply at Roche Diagnostics, highlighted the key problem facing the biopharmaceutical industry today. It is no wonder then that the promise of reduced costs and greater flexibility makes single-use technologies an increasingly attractive prospect for many.

Traditionally there has been a disconnect between the risk a drug won’t make it to market and the amount of money needed to start building facilities, but as Parrish M. Galliher, CTO Upstream at Xcellerex at GE Healthcare Life Sciences, emphasised at the event in April, “there is a certain amount of risk mitigation that single-use technology has provided”. Indeed, GE’s figures show that single-use implementation results in an average 32% saving on costs and a 30% increased capacity.

EXPLORE: Read our exlcusive interview with Parrish Galliher on the
challenges of increasing drug diversity

Continue reading “Single-use technology: The future of the bioprocessing industry?”

FDA Breakthrough Therapy Designation List 2016-2017

With new FDA Breakthrough Therapy Designations constantly being granted, we keep an up-to-date list of every approval. Check back for all the latest news and information.

(Last Updated: 2 February 2017)

Continue reading “FDA Breakthrough Therapy Designation List 2016-2017”

FDA Breakthrough Designation Approval: Challenges & Tips from Roche’s Dr. Niklas Engler

Since being signed into law on 9th July 2012, the FDA’s Breakthrough Designation has changed the face of drug development. In November 2013 Roche’s monoclonal antibody, Gazyva, became the first medicine designated as a Breakthrough Therapy and in the next two years a further 37 approvals were granted. This increasing trend has continued into 2016, with a raft of new drugs given approval in the first two months of the new year.

Roche continue to be at the forefront of the industry and have had a hand in more than one of these new approvals. In January their drug venetoclax (ABT-199), developed in partnership with AbbVie, received a third Breakthrough Therapy Designation for use in combination with hypomethylating agents, to treat patients with first-line acute myeloid leukemia (AML) who cannot receive high-dose chemotherapy. Then just this week it was announced that ocrelizumab (OCREVUS) has been given BTD approval for treatment of patients with primary progressive multiple sclerosis (PPMS).

Early last year we spoke to Dr. Niklas Engler, Head of European Technical Development for Biologics at Roche, about the company’s success with the FDA’s Breakthrough Designation and the challenges it creates.

Communication

“The FDA’s Breakthrough Designation has created a direct dialogue between sponsors and the agency. For Gazyva, which attacks targeted cells both directly and together with the body’s immune system, we had weekly exchanges; the speed in which the FDA was working with us was really impressive.”

Technical Support Teams

“The big challenges we face at the moment aren’t necessarily protein production, that is fairly well understood, it’s how technical teams support variations in clinical trials, whether it’s an accelerated programme such as FDA Breakthrough Designation, or heavily gated programmes where you don’t do any technical support for a long time and then have to catch up very quickly.”

Cost and Resources

“Obviously, the financial and personnel investments are huge for such as product so you have to make sure you have the right product in place and all the departments are aligned – technical, clinical and non-clinical development. Because once you jump on that train you accelerate very quickly. If you are not prepared you can really slow down any accelerated advantage you once had.”

Supplying the market

“If you want to go for a large indication like the PD-1 and PDL-1 markets, you need to make sure everything is in place to supply. This is a big topic for the FDA, they don’t want difficulties in supply.”

Want to find out more about this topic? Gargi Maheshwari (Executive Director, Biologics Process Development and Commercialisation, MSD) will be talking on Merck product Keytruda’s FDA Breakthrough Designation at BioProcess International European Summit in Vienna. Her session – “Keytruda – Acceleration of a Breakthrough Therapy…What to do when CMC is on the Critical Path” – is at 9.25am 11th April. Find out more and see the full agenda here.